<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980278</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00014299</org_study_id>
    <nct_id>NCT00980278</nct_id>
  </id_info>
  <brief_title>Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation</brief_title>
  <official_title>Cell Therapy Using Autologous Bone Marrow Cells Expanded Ex Vivo and Delivered Using Tricalcium Phosphate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if one's own bone marrow tissue can help
      regenerate (grow) bone in the area of the jaw where an implant will be placed. The name of
      the process is called Bone Repair Cell (BRC) Therapy. A sample of bone marrow tissue will be
      collected and sent to a laboratory where it will be processed to form more cells. These new
      cells will then be transplanted in the regenerative site or sinus floor augmentation site.
      The researchers are testing to see if these cells (BRC) will help form bone indicating. The
      research will also determine if the implant will be more stable in the area with new bone
      growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim is to promote bone regeneration, using Aastrom's proprietary Adult Stem Cell
      Therapy (AST) developed collaboratively with the University of Michigan, to enable placement
      of dental implants in patients who lack adequate alveolar bone. This project addresses
      specifically the placement of dental implants following bone regenerative sinus floor
      augmentation. This novel therapy mitigates the risks of other therapies, providing additional
      benefits of adequate cell numbers for high quality bone regeneration, and has the potential
      to become the new standard of care. In Aastrom's patented manufacturing technology, iliac
      bone marrow aspirates are expanded ex-vivo to enrich for adult multipotent cells (Bone Repair
      Cells- BRC) capable of regenerating bone and blood vessels. BRC will then be mixed with bone
      matrix graft extender, beta-tricalcium phosphate (β-TCP), before their implantation into the
      regenerative site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density of Bone Core</measure>
    <time_frame>4 months</time_frame>
    <description>Bone mineral density of bone core was measured by histological and µCT analyses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Volume Fraction of Bone Core</measure>
    <time_frame>4 months</time_frame>
    <description>Bone volume fraction of bone core histological and µCT analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Linear Radiographic Bone Height</measure>
    <time_frame>Screening and 1 week post-op from baseline</time_frame>
    <description>Change in linear radiographic bone heights were measured before and after bone graft reconstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinus Bone Volume</measure>
    <time_frame>Pre-baseline and within 2 weeks of 4 Month visit</time_frame>
    <description>CBCT was used to evaluated 3-D changes in the bone volume within the treated areas of the sinus cavity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Bone Volume: Initial Graft Volume Ratio</measure>
    <time_frame>4 months</time_frame>
    <description>Bone volume fraction of bone core histological and µCT analyses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Tooth Loss</condition>
  <arm_group>
    <arm_group_label>sinus lift plus dental implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sinus lift plus BRCs and dental implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sinus lift augmentation and dental implant</intervention_name>
    <description>transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
    <arm_group_label>sinus lift plus dental implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aastrom BRCs</intervention_name>
    <description>sinus augmentation, BRC application, dental implant</description>
    <arm_group_label>sinus lift plus BRCs and dental implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: 20-70 yrs

          -  Gender: Male and female

          -  Systemically healthy: Physical status according to the American Society of
             Anesthesiologists (ASA) I or II

          -  Requiring sinus augmentation to allow dental implant placement

          -  Missing teeth: Maxillary second premolar, maxillary first molar and/or maxillary
             second molar

          -  Remaining alveolar bone height: 2 to 6 mm

          -  Must be able and willing to follow study procedures and instructions

          -  Must have read, understood and signed an informed consent form

        Exclusion Criteria:

          -  Allergies or hypersensitivities to study related medications: dexamethasone,
             chlorhexidine, ibuprofen. For patients allergic to amoxicillin a comparable substitute
             antibiotic will be used

          -  Hematologic disorders/ blood dyscrasias

          -  Active infectious disease

          -  Liver or kidney dysfunction/failure- Patients will have blood drawn for serum
             laboratory tests, including creatinine, blood urea nitrogen, AST, ALT, and bilirubin.
             All of these must be within normal limits for a patient to be included in the study

          -  Laboratory values that will define normal renal and hepatic function, as well as
             criteria for exclusion of metabolic bone disease are consistent with those established
             by the University of Michigan Health System (UMHS). Normal clinical values will be
             used to help assure the health of all subjects in this trial. Potential subjects whose
             laboratory values fall outside the UMHS normal ranges and are considered clinically
             significant will be required to have medical clearance from their primary care
             provider prior to participation. Potential subjects presenting with clinically
             insignificant laboratory abnormalities will not require medical clearance and will be
             considered for inclusion in the study

          -  Endocrine disorders/dysfunctions (i.e. Type I and II diabetes)

          -  Cancer - The explicit definition of cancer used to exclude patients is consistent with
             that described by the National Cancer Institute (NCI), National Institutes of Health.
             According to NCI, cancer is any disease in which abnormal cells divide without control
             and invade nearby tissues (invasive disease). These include carcinomas, sarcomas,
             leukemias, and lymphomas. Any patient with a history of these invasive diseases will
             be excluded from the study.

          -  Patients who currently use bisphosphonates or have a history of bisphosphonate use
             will be excluded from the trial

          -  HIV+

          -  Metabolic Bone Diseases- Patients with metabolic bone diseases such as Paget's
             disease, hypercalcemia, moderate to severe vitamin D3 abnormalities or any other
             metabolic bone disease including osteoporosis and osteoporotic fractures will be
             excluded

          -  Pregnant women- Female patients who are of childbearing potential are excluded except
             those who are using hormonal or barrier methods of birth control (oral or parenteral
             contraceptives, diaphragm plus spermicide, or condoms). Pregnancy status will be
             determined with a urine test and patients who are pregnant will be excluded

          -  Patients with acute sinusitis, or presenting any sinus pathology that would
             contraindicate sinus augmentation

          -  Patients with congenital or metabolic bone disorders

          -  Current smokers (have smoked within 6 mos. of study onset)

          -  Subjects with congenital, or co-morbid conditions that would affect the study outcome
             or interpretation of study results will be excluded

          -  Individuals who have a BMI outside normal limits that deems them overweight (BMI &gt;25)
             will be excluded due to potential difficulties in locating appropriate surgical entry
             of the iliac crest during the bone marrow aspiration procedure

          -  Long term (&gt;2 weeks) use of antibiotics in the past 3 months

          -  Periodontally unstable subjects

          -  Subjects having any extractions in the possible treatment area in the past 3 months

          -  Subjects that are edentulous
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Giannobile, DDS, DMedSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michigan Center for Oral Health Research</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.umengage.org</url>
    <description>University of Michigan Clinical Research Database homepage</description>
  </link>
  <link>
    <url>http://www.dent.umich.edu/mcohr</url>
    <description>University of Michigan Center for Oral Health Research</description>
  </link>
  <reference>
    <citation>Albrektsson T, Brånemark PI, Hansson HA, Lindström J. Osseointegrated titanium implants. Requirements for ensuring a long-lasting, direct bone-to-implant anchorage in man. Acta Orthop Scand. 1981;52(2):155-70.</citation>
    <PMID>7246093</PMID>
  </reference>
  <reference>
    <citation>Amler MH. The time sequence of tissue regeneration in human extraction wounds. Oral Surg Oral Med Oral Pathol. 1969 Mar;27(3):309-18.</citation>
    <PMID>5251474</PMID>
  </reference>
  <reference>
    <citation>Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3213-8.</citation>
    <PMID>10725391</PMID>
  </reference>
  <reference>
    <citation>Krebsbach PH, Kuznetsov SA, Bianco P, Robey PG. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral Biol Med. 1999;10(2):165-81. Review.</citation>
    <PMID>10759420</PMID>
  </reference>
  <reference>
    <citation>Kaigler D, Mooney D. Tissue engineering's impact on dentistry. J Dent Educ. 2001 May;65(5):456-62. Review.</citation>
    <PMID>11425250</PMID>
  </reference>
  <reference>
    <citation>Mankani MH, Kuznetsov SA, Wolfe RM, Marshall GW, Robey PG. In vivo bone formation by human bone marrow stromal cells: reconstruction of the mouse calvarium and mandible. Stem Cells. 2006 Sep;24(9):2140-9. Epub 2006 Jun 8.</citation>
    <PMID>16763200</PMID>
  </reference>
  <reference>
    <citation>Marei MK, Nouh SR, Saad MM, Ismail NS. Preservation and regeneration of alveolar bone by tissue-engineered implants. Tissue Eng. 2005 May-Jun;11(5-6):751-67.</citation>
    <PMID>15998216</PMID>
  </reference>
  <reference>
    <citation>Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT, Hinrichs JE, McAllister BS, Murphy KS, McClain PK, Nevins ML, Paquette DW, Han TJ, Reddy MS, Lavin PT, Genco RJ, Lynch SE. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol. 2005 Dec;76(12):2205-15.</citation>
    <PMID>16332231</PMID>
  </reference>
  <reference>
    <citation>Atwood DA, Coy WA. Clinical, cephalometric, and densitometric study of reduction of residual ridges. J Prosthet Dent. 1971 Sep;26(3):280-95.</citation>
    <PMID>5284182</PMID>
  </reference>
  <reference>
    <citation>Evian CI, Rosenberg ES, Coslet JG, Corn H. The osteogenic activity of bone removed from healing extraction sockets in humans. J Periodontol. 1982 Feb;53(2):81-5.</citation>
    <PMID>6950085</PMID>
  </reference>
  <reference>
    <citation>Friedenstein AJ, Ivanov-Smolenski AA, Chajlakjan RK, Gorskaya UF, Kuralesova AI, Latzinik NW, Gerasimow UW. Origin of bone marrow stromal mechanocytes in radiochimeras and heterotopic transplants. Exp Hematol. 1978 May;6(5):440-4.</citation>
    <PMID>350596</PMID>
  </reference>
  <results_reference>
    <citation>Kaigler D, Avila-Ortiz G, Travan S, Taut AD, Padial-Molina M, Rudek I, Wang F, Lanis A, Giannobile WV. Bone Engineering of Maxillary Sinus Bone Deficiencies Using Enriched CD90+ Stem Cell Therapy: A Randomized Clinical Trial. J Bone Miner Res. 2015 Jul;30(7):1206-16. doi: 10.1002/jbmr.2464.</citation>
    <PMID>25652112</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>July 10, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2015</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>William Giannobile</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sinus lift</keyword>
  <keyword>tooth extraction</keyword>
  <keyword>dental implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Loss</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sinus Lift Plus Dental Implant</title>
          <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
        </group>
        <group group_id="P2">
          <title>Sinus Lift Plus BRCs and Dental Implant</title>
          <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sinus Lift Plus Dental Implant</title>
          <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
        </group>
        <group group_id="B2">
          <title>Sinus Lift Plus BRCs and Dental Implant</title>
          <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;20 and &lt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density of Bone Core</title>
        <description>Bone mineral density of bone core was measured by histological and µCT analyses</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sinus Lift Plus Dental Implant</title>
            <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
          </group>
          <group group_id="O2">
            <title>Sinus Lift Plus BRCs and Dental Implant</title>
            <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density of Bone Core</title>
          <description>Bone mineral density of bone core was measured by histological and µCT analyses</description>
          <units>mg/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".79" spread=".05"/>
                    <measurement group_id="O2" value=".78" spread=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Linear Radiographic Bone Height</title>
        <description>Change in linear radiographic bone heights were measured before and after bone graft reconstruction</description>
        <time_frame>Screening and 1 week post-op from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sinus Lift Plus Dental Implant</title>
            <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
          </group>
          <group group_id="O2">
            <title>Sinus Lift Plus BRCs and Dental Implant</title>
            <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Linear Radiographic Bone Height</title>
          <description>Change in linear radiographic bone heights were measured before and after bone graft reconstruction</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="2.8"/>
                    <measurement group_id="O2" value="12.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bone Volume Fraction of Bone Core</title>
        <description>Bone volume fraction of bone core histological and µCT analyses</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sinus Lift Plus Dental Implant</title>
            <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
          </group>
          <group group_id="O2">
            <title>Sinus Lift Plus BRCs and Dental Implant</title>
            <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Volume Fraction of Bone Core</title>
          <description>Bone volume fraction of bone core histological and µCT analyses</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".43" spread="8.1"/>
                    <measurement group_id="O2" value=".49" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sinus Bone Volume</title>
        <description>CBCT was used to evaluated 3-D changes in the bone volume within the treated areas of the sinus cavity</description>
        <time_frame>Pre-baseline and within 2 weeks of 4 Month visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sinus Lift Plus Dental Implant</title>
            <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
          </group>
          <group group_id="O2">
            <title>Sinus Lift Plus BRCs and Dental Implant</title>
            <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sinus Bone Volume</title>
          <description>CBCT was used to evaluated 3-D changes in the bone volume within the treated areas of the sinus cavity</description>
          <units>cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread=".9"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Bone Volume: Initial Graft Volume Ratio</title>
        <description>Bone volume fraction of bone core histological and µCT analyses</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sinus Lift Plus Dental Implant</title>
            <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
          </group>
          <group group_id="O2">
            <title>Sinus Lift Plus BRCs and Dental Implant</title>
            <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
          </group>
        </group_list>
        <measure>
          <title>Final Bone Volume: Initial Graft Volume Ratio</title>
          <description>Bone volume fraction of bone core histological and µCT analyses</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".2"/>
                    <measurement group_id="O2" value=".51" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sinus Lift Plus Dental Implant</title>
          <description>Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: N/A; only sinus augmentation and dental implant
Sinus lift augmentation and dental implant: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.</description>
        </group>
        <group group_id="E2">
          <title>Sinus Lift Plus BRCs and Dental Implant</title>
          <description>transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant
Aastrom BRCs: sinus augmentation, BRC application, dental implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="13" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Broken Tooth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Suture Loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain and Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flap Mobility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Non-restoreable Tooth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lack of Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Prosthesis Came Off</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ovarian Ulcer Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft Tissue Opening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Perforations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Giannobile, Chair Department of Periodontics and Oral Medicine</name_or_title>
      <organization>University of Michigan School of Dentistry</organization>
      <phone>734-763-2105</phone>
      <email>wgiannob@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

